Hepatitis Drugs Market

What is Biggest Trend Currently Witnessed in Hepatitis Drugs Market?


Hepatitis is a common condition around the world that most-prominently causes the liver to swell. There are several risk factors for this condition, including alcohol and drug usage and several infections. However, the most-common cause is the five hepatitis viruses: A, B, C, D, and E, themselves. These viruses can be transmitted into the host via contaminated food and water, infected blood and semen (via sex), unsterilized medical equipment, such as needles and catheters, and in utero.


For more information Hepatitis Drugs Market Research Report


As per the World Health Organization (WHO), hep A caused 7,134 deaths in 2016, while hep B carried a mortality of 887,000 in 2015. Similarly, hepatitis C claimed 399,000 lives in 2016, while hepatitis D affects around 5% of the people with an existing hep B infection every year. Additionally, hepatitis E carried a death count of 44,000 in 2015. Thus, with the growing prevalence of this disease, except for hep D, which has seen a reduction in the number of cases since the 1980s, the demand for various drugs to treat it is increasing.


Additionally, several international and national agencies around the world are working to make people aware of the different forms of the disease and increase the access to timely diagnosis and quality care. For instance, the WHO recognizes July 28th as World Hepatitis Day and conducts awareness campaigns. Moreover, it launched the Global Health Sector Strategy on Viral Hepatitis, 2016–2021 in May 2016, under which it aims to reduce the number of new hepatitis cases by 90% and the number of deaths by 65% by 2030. Similarly, May is recognized as Hepatitis Awareness Month in the U.S., wherein similar activities are conducted.


North America has been the most-productive hepatitis drugs market till now because it accounts for the most-advanced healthcare infrastructure and easy access to treatment. Additionally, the geriatric population (65 and above age group) in the region is set to cross 96.2 million by 2050 from 59.9 million in 2019, according to the World Population Ageing 2019 report of the United Nations (UN). Owing to their weakened immune system, the elderly become easy hosts for the hepatitis virus. Additionally, they need more-extensive care than the younger people, which is why they account for high hospitalization rates.

 

Hence, with the growing prevalence of hepatitis infections, the demand for the associated drugs will continue to surge.